These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14504063)

  • 1. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
    De Giorgi U; Rosti G; Monti M; Frassineti GL; Marangolo M
    Ann Oncol; 2003 Oct; 14(10):1588-9. PubMed ID: 14504063
    [No Abstract]   [Full Text] [Related]  

  • 2. Paclitaxel-induced nail changes: possible role of its vehicle (Cremophor EL).
    Minutilli E; Izzo F; Natoli G; Psaila A; Di Filippo F; Terzoli E
    Eur J Dermatol; 2006; 16(6):693-4. PubMed ID: 17229616
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative formulations of paclitaxel.
    Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
    Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
    Briasoulis E; Karavasilis V; Tzamakou E; Haidou C; Piperidou C; Pavlidis N
    Anticancer Drugs; 2002 Jun; 13(5):481-9. PubMed ID: 12045459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.
    Hussain S; Anderson DN; Salvatti ME; Adamson B; McManus M; Braverman AS
    Cancer; 2000 May; 88(10):2367-71. PubMed ID: 10820360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
    Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
    J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onycholysis associated with weekly administration of paclitaxel.
    Flory SM; Solimando DA; Webster GF; Dunton CJ; Neufeld JM; Haffey MB
    Ann Pharmacother; 1999 May; 33(5):584-6. PubMed ID: 10369623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and toxicology of Cremophor EL diluent.
    Dorr RT
    Ann Pharmacother; 1994 May; 28(5 Suppl):S11-4. PubMed ID: 7915152
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible drug-associated pancreatitis after paclitaxel-cremophor administration.
    Mills KM; Johnson DM; Middlebrooks M; Burton GV
    Pharmacotherapy; 2000 Jan; 20(1):95-7. PubMed ID: 10641981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL; Kossoff E
    Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
    Szebeni J; Muggia FM; Alving CR
    J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
    de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A
    Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
    Tejera A; Bosch RJ; López N; Herrera E
    Actas Dermosifiliogr; 2006 Oct; 97(8):536-8. PubMed ID: 17067535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nail alterations secondary to pactitaxel [corrected] therapy.
    Almagro M; Pozo JD; Garcia J; Vasquez A; Fonseca E
    Eur J Dermatol; 2000 Mar; 10(2):146-7. PubMed ID: 10694317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 96-hour paclitaxel infusions: at least 93 hours too long.
    O'Neil BH; Socinski MA
    Cancer Invest; 2003; 21(4):660-2. PubMed ID: 14533453
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-intensified weekly paclitaxel induces multiple nail disorders.
    Lüftner D; Flath B; Akrivakis C; Schweigert M; Prinz B; Mergenthaler HG; Petrides PE; Wernecke KD; Possinger K
    Ann Oncol; 1998 Oct; 9(10):1139-40. PubMed ID: 9834830
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical picture: nail changes secondary to docetaxel.
    Wasner G; Hilpert F; Baron R; Pfisterer J
    Lancet; 2001 Mar; 357(9260):910. PubMed ID: 11289346
    [No Abstract]   [Full Text] [Related]  

  • 20. Nail changes secondary to docetaxel (Taxotere).
    Correia O; Azevedo C; Pinto Ferreira E; Braga Cruz F; Polónia J
    Dermatology; 1999; 198(3):288-90. PubMed ID: 10393455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.